


PREPARATION AND PROPERTIES OF PHENYLALANINE-B³⁰-(HUMAN INSULIN)

Yu. P. Shvachkin, S. M. Funtova, A. M. Nikitina,
S. P. Krasnoshchekova, V. P. Fedotov, and A. I. Ivanova

UDC 547.964.4

In a directed experimental evaluation of the influence of the replacement of an aliphatic amino acid residue in the C-terminal part of the B-chain of insulin by an aromatic amino acid residue, we have prepared the previously unknown phenylalanine-B³⁰-(human insulin) and have investigated the biological activity of this analog, which differs from the natural hormone by the replacement of a L-threonine residue by a L-phenylalanine residue.

The phenylalanine B³⁰-insulin [I, R = de-ThrB³⁰-(human insulin)] was obtained by an enzymatic-chemical method using the tryptic transamidation reaction [1]. This reaction takes place on the interaction of porcine insulin [II, R = de-Ala B³⁰-(porcine insulin)] with L-phenylalanine tert-butyl ester (III) in an aqueous organic medium (water-dimethylformamide) at 25°C and pH 6.3. Under these conditions, the transamidation reaction takes place only at the Lys B²⁹ residue, and the undesirable side reaction at the Arg B²² residue does not proceed:



After the purification of the ester derivative of insulin (IV), formed as an intermediate, by ion-exchange chromatography on DEAE-Sephadex A-25, compound (IV) was subjected to chemical demasking with the aim of the exhaustive elimination of all the C-protective groups from the Phe B³⁰ residue. Demasking was effected by treating compound (IV) with trifluoroacetic acid at 20°C in the presence of anisole as protector. The phenylalanine-B³⁰-(human insulin) (I) formed was isolated from the reaction mixture by gel filtration on Sephadex G-25F. The course and degree of purification were monitored by thin-layer chromatography on silica gel, by electrophoresis in cellulose, and by disk electrophoresis in polyacrylamide gel.

After lyophilization of the eluate, phenylalanine-B³⁰-(human insulin) (I) was obtained in the analytically pure state.

Phenylalanine-B³⁰-(Human Insulin) (I). R_f 0.48 (C₅H₅N - C₄H₉OH - CH₃CO₂H H₂O, 10:15:3:12), 0.65 (C₅H₅N - CH₃COCH₃ - H₂O, 1:1:2), 0.34 iso-C₃H₇OH - 25% NH₄OH, 7:4), 0.88 iso-C₃H₇OH - 25% NH₄OH - H₂O, 7:4:6) (TLC on Silufol UV-254 plates; visualization with the Pauly reagent [2]. Electrophoretic mobility: 1.38 (electrophoresis on Whatman No. 1 paper pH 1.9 450 V, 7 mA, reference standard: the bis-S-sulfonate of the B-chain of human insulin). Amino acid analysis: Asp 2.77 (3), Thr 1.44 (2), Ser 2.36 (3), Glu 7.07 (7), Pro 1.09 (1), Gly 3.76 (4), Ala 1.05 (1), Val 4.02 (4), Ile 1.72 (2), Leu 6.00 (6), Tyr 3.51 (4), Phe 3.94 (4), Lys 1.03 (1), His 1.95 (2), Arg 0.89 (1). Results of a determination of C-terminal amino acids: Asn 0.97 (1), Phe 0.99 (1).

When tested for its convulsive effect in mice [3], the biological activity of compound (I) amounted to 95% (in comparison with the activity of the international standard).

LITERATURE CITED

1. Yu. P. Shvachkin, E. N. Voluiskaya, S. P. Krasnoshchekova, and A. M. Nikitina, *Khím. Prirod. Soedin.*, 792 (1983).
2. J. M. Stewart and J. D. Young, *Solid-Phase Peptide Synthesis*, W. H. Freeman, San Francisco (1969).
3. K. L. Smith, *Methods Horm. Res.*, 2, 439 (1962).

Institute of Experimental Endocrinology and Hormone Chemistry, Academy of Medical Sciences of the USSR, Moscow. Translated from *Khimiya Prirodnikh Soedinenii*, No. 3, pp. 465-466, May-June, 1987. Original article submitted December 10, 1986.